Compare BZ & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZ | QGEN |
|---|---|---|
| Founded | 2013 | 1986 |
| Country | China | Netherlands |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 10.2B |
| IPO Year | 2021 | 1998 |
| Metric | BZ | QGEN |
|---|---|---|
| Price | $14.13 | $41.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $26.00 | ★ $51.30 |
| AVG Volume (30 Days) | ★ 3.1M | 1.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 1.17% | ★ 5.85% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.60 | $8.23 |
| Revenue Next Year | $13.18 | $5.70 |
| P/E Ratio | ★ $22.61 | $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.29 | $38.13 |
| 52 Week High | $25.26 | $57.82 |
| Indicator | BZ | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 17.40 | 20.08 |
| Support Level | N/A | N/A |
| Resistance Level | $18.76 | $49.11 |
| Average True Range (ATR) | 0.50 | 0.97 |
| MACD | -0.13 | -0.80 |
| Stochastic Oscillator | 1.27 | 8.52 |
Kanzhun's Boss Zhipin job platform connects job seekers and employers. Boss Zhipin is China's largest online recruitment platform based on monthly active users, or MAU, and was established in 2014. Kanzhun earns revenue by providing services to enterprise customers primarily through its mobile app, which promotes engagement between recruiters and workers and operates on a recommendation basis powered by artificial intelligence. The platform specializes in transportation, logistics, construction, and service-based industries. About 85% of the companies looking to hire are small and medium-size enterprises. Its main competitors are 58.com, 51job, and Zhilian Zhaopin. Tencent has a 9.2% stake in Kanzhun.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).